For a medicine to be registered in a new country, manufacturers are generally required to provide substantial evidence to support the efficacy in the claimed indication in accordance with local regulatory standards. Substantial evidence is usually interpreted as statistically significant results with family-wise type I error rate controlled at twosided 5% from at least two adequately designed phase III confirmatory trials, or in special situations, one pivotal phase III confirmatory trial with statistical evidence considerably stronger than p < 0.05 (e.g. p < 0.001). 1, 2 Well-designed phase III confirmatory trials are crucial for marketing approval of a new medicine. However, phase III confirmatory trials are often time-consuming and very expensive. Even with good knowledge obtained from a series of adequately planned phase I and II studies, there may still be some uncertainty at the beginning of a phase III trial with respect to design and analysis.
During the past decade, there has been increasing interest in applying adaptive designs to the development of medicinal products. Adaptive design is a trial design that allows some type of prospectively planned mid-study changes without undermining the validity and integrity of the trial. Adaptive designs have potential utility in late-phase clinical trials. Since some planning parameters are imprecisely known at the design stage, adaptive design makes it possible to discover and rectify inappropriate assumptions, and maximize the chance of success.
In this article, some methodological issues with respect to sample size re-estimation, change in primary endpoint, interim dropping of treatment arms, change in statistical hypothesis, and change in the primary analysis are discussed. Several examples of design adaptation that have been encountered by the Center for Drug Evaluation in the past 3 years are presented. 
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Methodological Issues with Adaptive Design
The key considerations in regulatory setting for trials using adaptive design are that statistical methods for the control of type I error should be prespecified; correct estimates of treatment effect and associated confidence intervals should be available; the maintenance of the study blinding should be ensured; and methods for the assessment of consistency of treatment effect across all design modifications should be preplanned. 3 To cope with these considerations, the methodological issues with regards to several types of anticipated design modification are discussed here.
Sample size re-estimation
It is acknowledged that when planning a late phase II or even a phase III confirmatory trial, uncertainty may still exist about the parameter assumptions used for sample size calculation. The need to reassess sample size in an ongoing trial for some situations in which treatment response cannot be reliably predicted is understandable. However, the option of reassessing sample size based on the results of interim analysis should be justified at the planning stage, and the analysis method to control the type I error must be prespecified. Studies have shown that methods for blinded sample size reassessment based on updating a nuisance parameter such as within-group variance or pooled event rate can properly control the type I error. [4] [5] [6] [7] Blinded sample size re-estimations have an added advantage in that they can be performed by trial teams without use of a third party. On the other hand, sample size reassessment based on unmasking interim estimate of treatment difference may inflate the type I error. Since the integrity of the trial after observing the treatment difference is queried, the implications of unmasking sample size adjustment at the interim stage need to be carefully justified. Advanced statistical methods are available to protect the type I error when unmasking sample size recalculation is employed. 8, 9 However, increasing study sample size to achieve statistical significance does not mean that a clinically meaningful treatment effect is still preserved.
Change in primary endpoint
The primary endpoint is the variable that is capable of providing the most clinically relevant and convincing evidence. 10 It is usually not selected based on its ability to differentiate between treatment and control, but rather to describe a relevant clinical benefit in the treatment of the condition under study. Basically, a change in the primary endpoint after an interim analysis should not be acceptable. However, in some instances, there may be good justification for changing the primary endpoint, for example, if external information suggests that another variable may be better suited to measure patient benefit.
Interim dropping of treatment arm(s)
The flexibility to drop treatment arm(s) at interim analyses is highly desirable for late phase studies. From a regulatory perspective, it may be acceptable when the mechanism for dropping is based on safety concerns or is completely independent of the study primary outcome variable. Simulation studies have shown that interim dropping of a treatment arm based on internal data may have an impact on the overall type I error rate. 11 In particular, reallocating the unused α to the remaining arms for comparisons after dropping an arm will inflate the type I error rate substantially. Even though methodologies have been developed to control type I error rate, 12-14 a two-part phase II/III trial with an exploratory phase for dose selection followed by a confirmatory phase, in which the confirmatory phase has stand-alone significance, may provide the most convincing evidence of efficacy and is highly recommended.
Switching between superiority and noninferiority
The Committee for Proprietary Medicinal Products (CPMP) Points to Consider on Switching Between Superiority and Non-inferiority provides comprehensive discussion on this topic. 15 Generally, switching from noninferiority to superiority is straightforward and may be feasible if the trial has been properly designed and carried out in accordance with the strict requirements of a noninferiority trial. For such a design modification, analysis according to the intention-to-treat (ITT) principle is given greatest emphasis. Multiplicity adjustment is not necessary by using the closed testing principle. 16 On the other hand, switching from superiority to noninferiority will be more troublesome because the noninferiority margin with respect to the control treatment should be predefined. In this case, superiority and noninferiority tests should both be acceptable methods, by the local regulatory standards, for demonstrating the efficacy of the test treatment. In addition, the active control should demonstrate its usual level of efficacy and analysis according to the ITT principle, and per protocol (PP) analysis should provide similar findings. Wang et al 17 have indicated that when the sample size planned for testing superiority is increased to show noninferiority, it may inflate type I error. It is generally not acceptable to change the trial objective from superiority to noninferiority after interim results are available. Similarly, an interim change in noninferiority/equivalence margin based on the unmasking of treatment effect will be subjected to bias and is not acceptable.
Change in primary analysis
Changes in primary analysis (including changes in the primary efficacy population, the methods of missing data imputation, or the statistical method) should be avoided, even if performed before the blinding is broken. From a regulatory perspective, the preplanned analysis should be strictly adhered to unless there is strong evidence to show that prespecified analysis is inappropriate and may lead to inappropriate inference.
Experiences of the Center for Drug Evaluation
Over the past 3 years, the number of regulatory applications for design modification has been growing. These requests, either described directly in the original protocol or through a protocol amendment, encompass all types of adaptations. We present several cases here to exemplify the regulatory considerations.
Case 1 (sample size re-estimation)
A phase III, randomized, active-controlled trial was to be conducted in subjects with communityacquired pneumonia of sufficient severity to require hospitalization and treatment with intravenous antibiotics for a minimum of 3 days. The primary endpoint was clinical cure rate defined as the ratio of the number of clinically cured subjects to the total number of subjects in the clinically evaluable population at the test-of-cure visit.
A total of 670 subjects were required to ensure 266 evaluable subjects in each arm. A blinded interim analysis was planned when data from 70% (372) of the clinically evaluable subjects were available. If the overall observed cure rate was < 90%, then the sample size might be adjusted based on the observed rates. We accepted the adaptive trial design in this protocol because the design modification was preplanned and would be based on blinded interim analysis.
Case 2 (sample size re-estimation)
A phase III, randomized, multiple-dose, placebocontrolled, three-parallel-group study was to be conducted to assess the pain following total knee arthroplasty. One hundred subjects per group was estimated by assuming an SD of 2.2, with 90% power and a two-sided test with α = 0.05. A non-blinded interim analysis was to be performed, when 30% of subjects were either discharged from hospital or discontinued early before discharge, to investigate the assumptions used in the sample size estimation. The results from the interim analysis were to be used to adjust the sample size.
The proposed design adaptation was not accepted because of concerns over bias that resulted from knowledge of interim observed treatment effects. In addition, no statistical methodology was proposed to control type I error.
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Case 3 (change in primary endpoint)
A phase III, randomized, active-controlled study was conducted in patients with chronic stable angina pectoris. The original planned co-primary efficacy endpoints were "time to 1 mm ST segment depression" and "time to limiting angina". Two weeks after study initiation, the endpoint was redefined as "total exercise duration at the trough of drug activity", and the sample size was increased from 130 to 235 subjects per group. The main reason for this change was to comply with CPMP guidelines that became available at that time.
The application was accepted because the main reason for change was justifiable and the time for this change was sufficiently early that most of the data had not been collected.
Case 4 (change in primary endpoint)
The protocol was identical to that in case 2. The primary outcome variable was defined as the mean pain score reported by the subjects using an 11-point rating scale (0 = no pain, 10 = worst pain), at a time after surgery when the replaced knee was flexed to a fixed angle by an investigator or therapist using a goniometer. The time (48-96 hours after surgery) and the angle (45-100°) was determined after data analyses, for which at least 90% ITT subjects reached that angle of flexion and the difference between the 25% quartile and the 75% quartile of pain scores was at a maximum.
The design adaptation was not acceptable because the primary endpoint was determined after data analyses. The blinding may not have been maintained and the integrity of the study was questionable.
Case 5 (interim dropping of a treatment arm)
A two-stage adaptive design had been proposed to select the optimal dose at stage 1, and then to demonstrate superiority in overall survival at stage 2. Patients were to be randomized to test treatments (7.5 mg or 15 mg) or placebo on a 1:1:1 basis. The optimal dose was to be established in an interim analysis based on the efficacy and safety data at 18 weeks, after enrolment of the 210 th patient. After the optimal dose had been chosen, approximately 830 patients were to be randomly assigned to either the selected dose or placebo at a 1:1 ratio. The primary efficacy analysis was to be carried out to compare the overall survival between the selected dose group and placebo group for patients enrolled at stage 2 only. The design adaptation was acceptable because the final analysis, using only stage 2 data, would have had stand-alone significance.
Case 6 (interim dropping of a treatment arm)
A double-blind, randomized, phase II/III seamless study was to be conducted with three treatment groups (test drug 20 mg QD, 10 mg BID, and placebo). One interim analysis was planned to select the optimal dose at the end of the phase II stage, when a total of 300 patients (100 per group) had been followed for 6 months. The O'Brien and Fleming method was chosen to control type I error rate with a significance level set at 0.0051 for interim analysis and at 0.0415 for final analysis. An additional 300 patients were to be randomly assigned to either the selected dose or placebo group at a 1:1 ratio at the phase III stage. The final analysis was to combine data from both stages. Superiority of the test drug (selected dose) over placebo would be claimed if the two-sided p value was < 0.02075.
The design modification was acceptable because it did not reallocate the unused α to the remaining arm after interim dropping of a treatment arm.
Case 7 (switching from noninferiority to superiority)
A phase III, randomized, active-controlled study was to be conducted in subjects with uncomplicated pelvic inflammatory disease. The primary efficacy endpoint was the clinical cure rate at the test-of-cure visit. The noninferiority margin was predefined at 15%. If the lower limit of the twosided 95% confidence interval of the treatment difference (test drug minus control) was greater than −15% for the PP population and similar findings were observed for the ITT population,
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noninferiority of the test drug compared with active control would be claimed. If the lower limit for the ITT population was > 0 and similar findings were observed for the PP population, then the superiority of the test drug over active control would be claimed.
The proposed design modification was acceptable because it would simultaneously test noninferiority and superiority using a closed testing procedure. In addition, the study was designed and carried out in accordance with the requirements of a noninferiority trial, which would use data of higher quality in the analyses.
Case 8 (change in primary endpoint and primary analysis)
A phase III randomized, double-blind, placebocontrolled study was conducted in patients with advanced breast cancer. The primary efficacy endpoint was the number of 12-week periods with new bone complication of metastatic bone disease. Ordinal logistic regression would be employed for the primary analysis. After a protocol amendment, the primary outcome measure was changed into AOSR (altered ordinary standard ratio), defined as follows:
Wilcoxon rank sum test was to be applied as the new primary analysis. The main argument for this design modification was that the original analysis would ignore the total observation time and might underestimate the number of eventful periods in those who discontinued early. This would lead to an inappropriate inference if the dropout rates between the two study groups were imbalanced.
The argument was deemed justifiable, and this design modification was accepted.
Concluding Remarks
A protocol is a plan that details how a clinical trial will be carried out and how the data will be collected and analyzed. It is the most important document of the trial since it ensures the adequacy and validity of the clinical investigations, in terms of their planning, operation and analysis. Adherence to the protocol is crucial during the conduct of a clinical trial. It ensures that the conclusions drawn from the trial results are unbiased and not misleading.
Although traditional nonadaptive designs minimize statistical and operational biases, adaptive designs may reflect real clinical practice in current clinical development. Adaptive designs have been highly desirable for most biopharmaceutical companies in recent years. However, they are clearly not suited to all clinical trials. From a regulatory point of view, adaptive designs should be encouraged for phase I and II trials, for better exploration of drug information, so as to be optimally used in the planning of phase III confirmatory trials. When design adaptation is employed in phase III confirmatory trials, much more careful planning is needed than in traditional nonadaptive trials. 18 It should be made independent of the observed treatment effect where possible. Once unmasking is necessary, careful consideration needs to be given to preserve the integrity of the trial. Moreover, the procedure of adaptations selected should always ensure that the overall probability of type I error rate is controlled. It is advisable that the number of adaptations should be limited to maintain the confirmatory nature in late drug development. Any potential changes to the trial and the statistical procedure should be prespecified in the protocol. The sponsor should consult with regulatory agencies at the protocol design stage.
AOSR
Periods with new bone complications Total observation = t time, in periods
